Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) - Epidemiology Forecast - 2036

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Insights and Trends

• The incidence of idiopathic IC-MPGN remains unknown, the estimated global annual incidence of C3G ranges from 1 to 3 cases per million individuals. The risk of progression to kidney failure is substantial, with up to 30%-35% of patients with C3G or idiopathic IC-MPGN developing kidney failure within 10 years of diagnosis.
• IC-MPGN is classified as idiopathic only after an exhaustive evaluation fails to identify an underlying cause, with emerging evidence suggesting that a subset of cases may be driven by dysregulation and overactivation of the alternative complement pathway.
• According to the registry in the UK, the minimal point prevalence is 1.3/100,000 for MPGN UK-wide.
• According to DelveInsight's estimates, males represented more than 50% of the total IC-MPGN cases in the US in 2025.
• Approximately 50% of people living with C3G and primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis therapy.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Epidemiology Forecast in the 7MM

• 2025 Incident Cases of IC-MPGN: ~7,000
• IC-MPGN Growth Rate (2026-2036): 2% CAGR

DelveInsight's 'Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the IC-MPGN, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Understanding and Diagnosis Algorithm

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Overview and Diagnosis

Primary IC-MPGN is rare, chronic kidney disorder. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. IC-MPGN can be primary (idiopathic) or secondary to underlying conditions such as infections, autoimmune diseases, or malignancies. Clinically, patients often present with proteinuria, hematuria, hypertension, and declining kidney function, and the disease may progressively lead to chronic kidney disease (CKD) or end-stage kidney failure if not adequately managed.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Diagnosis

The diagnosis of IC-MPGN involves a combination of clinical evaluation, laboratory testing, and histopathological confirmation. Initial findings typically include proteinuria (often nephrotic range), microscopic hematuria, and reduced kidney function, along with possible low complement levels (especially C3 and C4). However, the gold standard for diagnosis is a kidney biopsy, which reveals characteristic features such as mesangial proliferation, thickened capillary walls, and immune complex deposits. Immunofluorescence microscopy demonstrates the presence of immunoglobulins (e.g., IgG) along with complement components, helping differentiate IC-MPGN from C3 glomerulopathy, where C3 deposition predominates.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Epidemiology

Key Findings from IC-MPGN Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, in 2025, the total number of diagnosed prevalent cases of IC-MPGN in the 7MM were ~7,000.
• In 2025, the US accounted for the highest number of diagnosed prevalent cases of IC-MPGN, with ~3,500 cases, followed by Japan.
• The cases of IC-MPGN are more prevalent in adults than in pediatrics.

Scope of the Report:

• The report covers a segment of a descriptive overview of IC-MPGN, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of IC-MPGN? What will be the growth opportunities across the 7MM concerning the patient population with IC-MPGN?
• What is the historical and forecasted IC-MPGN patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.